Rahul Seth1, Hans Messersmith2, Varinder Kaur3, John M Kirkwood4,5, Ragini Kudchadkar6, Jennifer Leigh McQuade7, Anthony Provenzano8, Umang Swami9, Jeffrey Weber10, Krishna C Alluri11, Sanjiv Agarwala12, Paolo A Ascierto13, Michael B Atkins14, Nancy Davis15, Marc S Ernstoff16, Mark B Faries17,18, Jason S Gold19, Samantha Guild20, David E Gyorki21, Nikhil I Khushalani22, Michael O Meyers23, Caroline Robert24,25, Mario Santinami26, Amikar Sehdev27, Vernon K Sondak22, Gilliosa Spurrier28, Katy K Tsai29, Alexander van Akkooi30, Pauline Funchain31. 1. State University of New York Upstate Medical University, Syracuse, NY. 2. American Society of Clinical Oncology, Alexandria, VA. 3. University of Virginia, Charlottesville, VA. 4. University of Pittsburgh School of Medicine, Pittsburgh, PA. 5. University of Pittsburgh Medical Center, Hillman Cancer Institute, Pittsburgh, PA. 6. Emory University, Atlanta, GA. 7. University of Texas MD Anderson Cancer Center, Houston, TX. 8. Columbia Presbyterian Clinical Associates, Bronxville, NY. 9. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. 10. Laura and Isaac Perlmutter Cancer Center at New York University, Langone Health, New York, NY. 11. St Luke's Mountain States Tumor Institute, Boise, ID. 12. Lewis Katz School of Medicine at Temple University, Philadelphia, PA. 13. Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. 14. Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC. 15. Vanderbilt University Medical Center, Nashville, TN. 16. Roswell Park Cancer Institute, Buffalo, NY. 17. The Angeles Clinic and Research Institute, Los Angeles, CA. 18. Cedars Sinai Medical Center, Los Angeles, CA. 19. Veterans Administration Boston Healthcare System, West Roxbury, MA. 20. AIM at Melanoma Foundation, Frisco, TX. 21. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 22. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 23. University of North Carolina School of Medicine, Chapel Hill, NC. 24. Gustave Roussy Cancer Centre, Villejuif, France. 25. Paris-Saclay University, Villejuif, France. 26. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 27. Indiana University School of Medicine, Indianapolis, IN. 28. Melanome France, Teilhet, France. 29. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. 30. Netherlands Cancer Institute, Amsterdam, the Netherlands. 31. Cleveland Clinic, Cleveland, OH.
Abstract
PURPOSE: To provide guidance to clinicians regarding the use of systemic therapy for melanoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS: A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanoma. RECOMMENDATIONS: In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while either of those two agents or the combination of dabrafenib and trametinib should be offered in BRAF-mutant disease. No recommendation could be made for or against the use of neoadjuvant therapy in cutaneous melanoma. In the unresectable/metastatic setting, ipilimumab plus nivolumab, nivolumab alone, or pembrolizumab alone should be offered to patients with BRAF wild-type cutaneous melanoma, while those three regimens or combination BRAF/MEK inhibitor therapy with dabrafenib/trametinib, encorafenib/binimetinib, or vemurafenib/cobimetinib should be offered in BRAF-mutant disease. Patients with mucosal melanoma may be offered the same therapies recommended for cutaneous melanoma. No recommendation could be made for or against specific therapy for uveal melanoma. Additional information is available at www.asco.org/melanoma-guidelines.
PURPOSE: To provide guidance to clinicians regarding the use of systemic therapy for melanoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS: A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanoma. RECOMMENDATIONS: In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while either of those two agents or the combination of dabrafenib and trametinib should be offered in BRAF-mutant disease. No recommendation could be made for or against the use of neoadjuvant therapy in cutaneous melanoma. In the unresectable/metastatic setting, ipilimumab plus nivolumab, nivolumab alone, or pembrolizumab alone should be offered to patients with BRAF wild-type cutaneous melanoma, while those three regimens or combination BRAF/MEK inhibitor therapy with dabrafenib/trametinib, encorafenib/binimetinib, or vemurafenib/cobimetinib should be offered in BRAF-mutant disease. Patients with mucosal melanoma may be offered the same therapies recommended for cutaneous melanoma. No recommendation could be made for or against specific therapy for uveal melanoma. Additional information is available at www.asco.org/melanoma-guidelines.
Authors: Alexander C J van Akkooi; Tina J Hieken; Elizabeth M Burton; Andrew J Spillane; Merrick I Ross; Charlotte Ariyan; Paolo A Ascierto; Salvatore V M A Asero; Christian U Blank; Matthew S Block; Genevieve M Boland; Corrado Caraco; Sydney Chng; B Scott Davidson; Joao Pedreira Duprat Neto; Mark B Faries; Jeffrey E Gershenwald; Dirk J Grunhagen; David E Gyorki; Dale Han; Andrew J Hayes; Winan J van Houdt; Giorgos C Karakousis; Willem M C Klop; Georgina V Long; Michael C Lowe; Alexander M Menzies; Roger Olofsson Bagge; Thomas E Pennington; Piotr Rutkowski; Robyn P M Saw; Richard A Scolyer; Kerwin F Shannon; Vernon K Sondak; Hussein Tawbi; Alessandro A E Testori; Mike T Tetzlaff; John F Thompson; Jonathan S Zager; Charlotte L Zuur; Jennifer A Wargo Journal: Ann Surg Oncol Date: 2022-01-28 Impact factor: 5.344
Authors: Lisa Haas; Anais Elewaut; Camille L Gerard; Christian Umkehrer; Lukas Leiendecker; Malin Pedersen; Izabela Krecioch; David Hoffmann; Maria Novatchkova; Mario Kuttke; Tobias Neumann; Ines Pires da Silva; Harriet Witthock; Michel A Cuendet; Sebastian Carotta; Kevin J Harrington; Johannes Zuber; Richard A Scolyer; Georgina V Long; James S Wilmott; Olivier Michielin; Sakari Vanharanta; Thomas Wiesner; Anna C Obenauf Journal: Nat Cancer Date: 2021-07-15
Authors: Matthew C Hynes; Paul Nguyen; Patti A Groome; Yuka Asai; Meaghan E Mavor; Tara D Baetz; Timothy P Hanna Journal: BMC Cancer Date: 2022-07-01 Impact factor: 4.638